Beta Bionics (BBNX) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales reached $17.6M, up 36% year-over-year, driven by robust demand for the iLet and strong new patient starts, which grew 48% year-over-year to 3,853, with 71% from MDI users.

• Gross profit increased to $9.0M, but gross margin declined to 50.9%–51% due to a higher pharmacy/PBP channel mix.

• Net loss widened to $28.7M, reflecting higher operating expenses and warrant liability revaluation.

• Completed IPO and private placement in January 2025, raising $206M in net proceeds, supporting commercialization and R&D.

• Installed customer base grew to 19,151, up 291% year-over-year.

Financial highlights

• Q1 2025 net sales: $17.6M (+36% YoY); single-use products accounted for 43% of sales.

• Gross margin: 50.9%–51% (down from 55.7%–56% YoY); gross profit: $9.0M.

• Operating expenses: $27.6M (+66% YoY), with R&D at $7.6M, sales/marketing at $13.4M, and G&A at $6.6M.

• Adjusted EBITDA: $(15.5)M (negative 88% of sales); net loss per share: $(0.93).

• Cash, cash equivalents, and investments totaled $295.5M as of March 31, 2025.

Outlook and guidance

• Full-year 2025 revenue guidance raised to $82M–$87M (prior $80M–$85M).

• Gross margin outlook increased to 50%–53% (prior at least 50%).

• Pharmacy/PBP channel mix guidance raised to 22%–25% of new patient starts (prior >20%).

• Existing cash and investments expected to fund operations through the first half of 2028.

• Sequential growth in new patient starts expected in Q2, with new sales territories contributing.